

Purified anti-human CD274 (B7-H1, PD-L1) (Maxpar[®] Ready) Antibody

| | |
|--------------------------|--|
| Catalog# / Size | 329719 / 100 µg |
| Clone | 29E.2A3 |
| Regulatory Status | RUO |
| Other Names | Programmed cell death ligand 1 (PD-L1), B7 homolog 1 (B7-H1) |
| Isotype | Mouse IgG2b, κ |
| Description | CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |

Product Details

| | |
|---------------------------------|--|
| Verified Reactivity | Human |
| Reported Reactivity | African Green, Baboon, Cynomolgus, Rhesus |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Immunogen | Full length human PD-L1 |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and EDTA. |
| Preparation | The antibody was purified by affinity chromatography. |
| Concentration | 1.0 mg/ml |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C. |
| Application | FC - Quality tested CyTOF[®] - Verified |
| Recommended Usage | This product is suitable for use with the Maxpar[®] Metal Labeling Kits . For metal labeling using Maxpar [®] Ready antibodies, proceed directly to the step to Partially Reduce the Antibody by adding 100 µl of Maxpar [®] Ready antibody to 100 µl of 4 mM TCEP-R in a 50 kDa filter and continue with the protocol. Always refer to the latest version of Maxpar [®] User Guide when conjugating Maxpar [®] Ready antibodies. |
| Application Notes | <p>Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region⁵. Additional reported applications (for the relevant formats) include: blocking¹⁻³ and immunohistochemical staining of acetone-fixed frozen sections¹. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748).</p> <p>It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor[®] 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the Alexa Fluor[®] 700 conjugate of interest.</p> <p>Clone 29E.2A3 does not work in Western blot applications⁷.</p> |
| Additional Product Notes | Maxpar [®] is a registered trademark of Standard BioTools Inc. |
| Application References | 1. Brown J, <i>et al.</i> 2003. <i>J. Immunol.</i> 170:1257. (FC, IHC, Block) 2. Radziewicz H, <i>et al.</i> 2007. <i>J. Virol.</i> 81:2545. (Block) |
| (PubMed link indicates | |

- BioLegend citation)**
3. Nakamoto N, *et al.* 2009. *PLoS Pathog.* 5:e1000313. (Block)
 4. Barsoum IB, *et al.* 2014. *Cancer Res.* 74:665. [PubMed](#)
 5. Haile, S *et al.* 2013. *J. Immunol.* 191:2829.
 6. RL M, *et al.* 2015. *PNAS.* 112:6506-6514. [PubMed](#)
 7. Mahoney KM, *et al.* 2015. *Cancer Immunol. Res.* 3:1308.

- Product Citations**
1. Alcántara-Hernández M *et al.* 2017. *Immunity.* 47(6):1037-1050 . [PubMed](#)
 2. Gañán-Gómez I, *et al.* 2022. *Nat Med.* . [PubMed](#)
 3. Jordan S, *et al.* 2020. *Cell.* 178(5):1102-1114.e17.. [PubMed](#)
 4. Roussel M, *et al.* 2021. *Cell Reports Medicine.* 2(6):100291. [PubMed](#)
 5. Mishra A, *et al.* 2021. *Cell.* 184(13):3394-3409.e20. [PubMed](#)

RRID AB_2565429 (BioLegend Cat. No. 329719)

Antigen Details

| | |
|---------------------------|--|
| Distribution | T cells, B cells, NK cells, monocytes/macrophages, granulocytes and dendritic cells |
| Function | CD274 is involved in the costimulatory signal, essential for T lymphocyte proliferation and production of IL-10 and IFN- γ , in an IL-2-dependent and a PD-1-CD1-independent manner. Its interaction with PD-1-CD1 inhibits T-cell proliferation and cytokine production. |
| Ligand/Receptor | PD-1 (PDCD1) |
| Cell Type | B cells, Dendritic cells, Fibroblasts, Granulocytes, Macrophages, Monocytes, NK cells, T cells |
| Biology Area | Cancer Biomarkers, Costimulatory Molecules, Immunology |
| Molecular Family | Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors |
| Antigen References | 1. Sharpe A, <i>et al.</i> 2007. <i>Nat. Immunol.</i> 8:239. |
| Gene ID | 29126 |


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)


Other Formats

Purified anti-human CD274 (B7-H1, PD-L1), Biotin anti-human CD274 (B7-H1, PD-L1), PE anti-human CD274 (B7-H1, PD-L1), APC anti-human CD274 (B7-H1, PD-L1), Brilliant Violet 421™ anti-human CD274 (B7-H1, PD-L1), Ultra-LEAF™ Purified anti-human CD274 (B7-H1, PD-L1), PE/Cyanine7 anti-human CD274 (B7-H1, PD-L1), Purified anti-human CD274 (B7-H1, PD-L1) (Maxpar® Ready), Brilliant Violet 711™ anti-human CD274 (B7-H1, PD-L1), Brilliant Violet 605™ anti-human CD274 (B7-H1, PD-L1), GoInVivo™ Purified anti-human CD274 (B7-H1, PD-L1), PE/Dazzle™ 594 anti-human CD274 (B7-H1, PD-L1), Brilliant Violet 785™ anti-human CD274 (B7-H1, PD-L1), Brilliant Violet 510™ anti-human CD274 (B7-H1, PD-L1), PerCP/Cyanine5.5 anti-human CD274 (B7-H1, PD-L1), Brilliant Violet 650™ anti-human CD274 (B7-H1, PD-L1), Alexa Fluor® 594 anti-human CD274 (B7-H1, PD-L1), TotalSeq™-A0007 anti-human CD274 (B7-H1, PD-L1), TotalSeq™-B0007 anti-human CD274 (B7-H1, PD-L1), TotalSeq™-C0007 anti-human CD274 (B7-H1, PD-L1), TotalSeq™-D0007 anti-human CD274 (B7-H1, PD-L1), PE/Fire™ 810 anti-human CD274 (B7-H1, PD-L1) Antibody, PE/Cyanine5 anti-human CD274 (B7-H1, PD-L1), Spark YG™ 570 anti-human CD274 (B7-H1, PD-L1)

Product Data



Human PBMCs were incubated for three days in media alone (top) or with PHA (bottom) and then cells were stained with 154Sm-anti-CD45 (HI30) and 175Lu-anti- CD274/PD-L1 (29E.2A3).



For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587